Colorectal Cancer Trial, Recruiting NCT05963191 Sponsor: PERROD Guillaume Condition: Colorectal Cancer
Back to Colorectal Cancer

Colorectal Cancer Trial, Recruiting

NCT05963191
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who have a confirmed harmful genetic mutation in one of the following genes: MLH1, MSH2, MSH6, PMS2, or EpCAM
  • People who are of legal adult age at the time their colonoscopy is prescribed
  • People who agree to take part in the study
  • People who are enrolled in or covered by a social security (health insurance) scheme
  • People who have given their free, fully informed, and clearly expressed consent to participate

Who may not be able to join:

  • People who have had their entire large bowel removed and had a surgical reconnection involving the small intestine
  • People who have a history of Crohn's disease or ulcerative colitis (chronic inflammatory bowel conditions)
  • People who have a known allergy or intolerance to polyethylene glycol or ascorbic acid (ingredients commonly found in bowel-cleansing preparations)
  • People who are unable to complete a split-dose bowel preparation (the process of cleaning out the bowel before a colonoscopy, done in two separate sessions)
  • People whose bowel preparation was not adequate enough, based on a specific scoring system used to measure bowel cleanliness (confirm with trial site)
  • People who are under legal guardianship or are otherwise legally protected
  • People who do not understand French or are unable to read
  • People who are not enrolled in a social security system
  • People who are pregnant

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 21 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Phone: +33 1 56 09 34 17

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
PERROD Guillaume
Registry
ClinicalTrials.gov
Start date
18 April 2024
Est. completion
18 April 2025

Where this trial is recruiting

🇫🇷 France

Primary endpoints

to evaluate the effectiveness of the CAD EYE system in screening for neoplastic lesions in Lynch syndrome.

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 21 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov